Communication Officielle
Mercredi 21 octobre 2020, 18h05 (il y a 42 mois) THERANEXUS : THERANEXUS AND BBDF OBTAIN EUROPEAN "ORPHAN MEDICINAL PRODUCT" DESIGNATION FOR BBDF-101 IN BATTEN DISEASE
Under the agreement between Theranexus and BBDF, Theranexus has an exclusive, global license for the development and commercial use of its drug candidate BBDF-101 for juvenile Batten disease. BBDF-101 is a proprietary combination of trehalose and miglustat, two active ingredients which each have a specific role and work in synergy to restore normal metabolic activity in brain cells. "After obtaining Orphan Drug Designation from the FDA in August, we are delighted to have secured the same status for Europe. During the summer we launched preclinical studies to confirm the safety of BBDF-101 over a long exposure time, with the aim of launching the clinical program in 2021," explains Franck Mouthon, Chairman and CEO of Theranexus.
"Orphan" drugs are aimed at diagnosing, preventing or treating very serious or life-threatening rare diseases that affect no more than 5 in 10,000 people in the European Union. This status gives Theranexus ten years of market exclusivity in the European Union once the drug has been granted marketing authorization. The Company will also receive scientific advice from the European Medicines Agency (EMA) to ensure that it complies with European regulatory requirements and will have direct access to the centralized marketing authorization procedure. Orphan designation also exempts the Company from paying the fees associated with the submission of the marketing authorization application.
Cette publication dispose du service "Actusnews SECURITY MASTER". - SECURITY MASTER Key : l3CelMVvYmyXyG5tk5eXmZRmmphqmWfKZWOWyWJpZZ Ua29inWmUbcbKZm9mm21t - Pour contrôler cette clé : https://www.security-master-key.com. Communiqué intégral et original au format PDF : Télécharger le PDF Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Flux Rss METABOLIC EXPLORER : |
|